Clinical Trial Update: Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating oral treprostinil for pulmonary hypertension in patients with sickle cell disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension Associated with Sickle Cell Disease

Drugs mentioned

• Oral treprostinil (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Pulmonary Hypertension Associated With Sickle Cell Disease | Phase 3 | Status: WITHDRAWN